Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Brii Bio Forms $128.5 Million Collaboration for Therapeutic Hepatitis B Vaccine

publication date: Dec 6, 2018

Brii Biosciences, a China-US startup, has entered a $128.5 million agreement for China rights to an immuno-therapeutic hepatitis B vaccine from VBI Vaccines of Cambridge, MA. Brii made a $4 million upfront payment and an equity investment of $11 million in VBI, plus will pay up to $117.5 million in milestones. Brii made its debut earlier this year with $260 million in initial capital. It also announced options for China rights to four biotech infectious disease assets from Vir of San Francisco, including a hepatitis B vaccine. More details....

Stock Symbol: (NSDQ: VBIV)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

ChinaBio® Events

ChinaBio Partnering Forum 2020

Content Availbalble Until Dec. 21, 2020